贝林妥欧单抗治疗儿童急性淋巴细胞白血病的安全性分析及药学监护OACSTPCD

Objective:To investigate the adverse drug reactions and management measures of blinatumomab in the treatment of acute lymphoblastic leukemia(ALL)in children,in order to provide reference for pharmaceutical care.Methods:PubMed,EMBase,CNKI,Wanfang and Sinomed databases were retrieved to collect the relevant literature.Clinical trial data were retrieved from ClinicalTrials.gov,and pharmacovigilance data were retrieved from U.S.Food and Drug Administration Adverse Event Reporting System(FAERS).The types,incidence and treatment measures of adverse drug reactions that may occur in the treatment of ALL with belintuozumab were reviewed.Results:Compared with traditional chemotherapy regimens,the incidence of total adverse drug reactions of belintuozumab was lower and the overall safety was better.The most significant adverse drug reactions included cytokine release syndrome,immune effector cell-related neurotoxic syndrome,hypogammaglobulinemia,decreased blood count and infection.Based on pharmacological properties,early prevention,recognition,rapid symptomatic management and patient education were the focus of pharmaceutical care.Conclusion:The safety of belintuozumab in the treatment of children with ALL is good,early detection and symptomatic management of pharmaceutical care are crucial to reduce adverse drug reactions.